CSE Bulletin: Fundamental Change - Glenbriar Technologies Inc./Love Pharma Inc.

 

Le 29 septembreSeptember 2021) Love Pharma Inc., the issuer resulting from a Fundamental Change of Glenbriar Technologies Inc. (GTI.X), has been approved for listing.

 

Listing and disclosure documents will be available at www.thecse.com on the trading date.

 

Love Pharma Inc., is a specialized health and wellness company offering pharmaceutical and therapeutic products with proven technologies for which it has the exclusive rights to produce, package and sell thoughout Europe, North America and the United Kingdom. Many of the products are market-ready, with proven history of significant sales. The Company is focused on the global sexual wellness and enhancement market.

 

_________________________________

 

Love Pharma Inc., l'émetteur résultant d'un changement fondamental de Glenbriar Technologies Inc. (GTI.X), a été approuvé pour inscription.

 

Les documents de cotation et d'information seront disponibles sur www.thecse.com à la date de négociation.

 

Love Pharma Inc. est une société spécialisée dans la santé et le bien-être offrant des produits pharmaceutiques et thérapeutiques dotés de technologies éprouvées pour lesquelles elle détient les droits exclusifs de production, d'emballage et de vente en Europe, en Amérique du Nord et au Royaume-Uni. De nombreux produits sont prêts à être commercialisés, avec des antécédents avérés de ventes importantes. La Société se concentre sur le marché mondial du bien-être et de l'amélioration sexuelle.

 
                                
 Issuer/Émetteur:  Love Pharma Inc.
 Security Type/Titre:  

Common Shares/Actions ordinaires

 
 Symbol(s)/Symbole(s):  LUV
 Number of securities issued and outstanding/ Titres émis et en circulation:  314 919 945
 Number of Securities reserved for issuance/ Titres réservés pour émission:  73 626 130
 CSE Sector/Catégorie:  Life Sciences/Sciences Biologiques
 CUSIP :  547153 10 6
 ISIN :  CA 547153 10 6 4
 Old/Vieux CUSIP& ISIN:  377904107/CA3779041076
 Boardlot/Quotité:  1000
 Consolidation:  1 New for 2 Old /1 nouveau pour 2 ancien
 Trading Currency/Monnaie de négociation:  CDN$/$CDN
 Trading Date/Date de negociation:  Le 30 septembre/September 2021
 Other Exchanges/Autres marches:  N/A
 Fiscal Year end /Clôture de l'exercice financier:  Le 30 septembre/September
 Transfer Agent/Agent des transferts:  Odyssey Trust Company
 

 

 

The Exchange is accepting Market Maker applications for LUV. Please email: Trading@theCSE.com 

 

If you have any questions or require further information please contact Listings at (416) 367-7340 or E-mail: Listings@thecse.com 

 

Pour toute question, pour obtenir de l'information supplémentaire veuillez communiquer avec le service des inscriptions au 416 367-7340 ou par courriel à l'adresse: Listings@thecse.com 

 

 

News Provided by Newsfile via QuoteMedia

The Conversation (0)
Stethoscope on stacked gold coins, symbolizing healthcare costs or medical finance.

Trump Tariffs to Raise US Medical Device Costs, Hospitals Hold Off on Stockpiling

President Donald Trump’s new round of tariffs —this time targeting copper— has intensified concerns about rising costs across key sectors, including healthcare.

But despite significant price pressures on steel, aluminum, and now copper, all vital to medical device production, there is no indication that US hospitals are stockpiling equipment ahead of expected price hikes, according to recent findings from GlobalData.

Keep reading...Show less
Actinogen

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer’s disease trial and interim analysis timeline

Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that the 100th participant in its pivotal XanaMIA phase 2b/3 randomized trial of Xanamem® for Alzheimer’s disease (AD) has now passed all screening tests and is scheduled for randomization and treatment in July. This establishes the timeline for the planned safety and efficacy futility interim analysis by an independent Data Monitoring Committee (DMC).

Keep reading...Show less
Emyria Limited

Medibank to Fund Emyria’s PTSD Program at Perth Clinic

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering innovative mental health treatments, is pleased to announce that Medibank Private Limited (“Medibank”), Australia’s largest private health insurer, has commenced funding for eligible customers to access Emyria’s Empax PTSD care program delivered in association with Perth Clinic.

Keep reading...Show less
ASX:HIQ

HITIQ Announces Exclusive Global Agreement with Shock Doctor for PROTEQT Instrumented Mouthguard

Common Shareholder Questions – Entitlement Offer

HITIQ Limited (ASX: HIQ) (HITIQ or the Company), a pioneer in concussion management, proudly announces an exclusive global agreement with Shock Doctor, the world’s leading mouthguard innovator. This landmark agreement marks Shock Doctor’s two-year effort to design a mouthguard that will integrate HITIQ’s PROTEQT technology. The result is a fully developed, market-ready solution that merges HITIQ’s smart sensor technology with Shock Doctor’s unmatched global production partner capabilities.

Keep reading...Show less
HeartSciences Inc

HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis

Aortic Stenosis is a Serious and Widespread Condition; The AI-ECG Algorithm Offers a Powerful Diagnostic Solution Designed for Seamless Integration with Hospital EHR Systems

Keep reading...Show less
Zoono Group

Exclusive UK Packaging Agreement signed between Sharpak Aylesham Limited, Zoono, and OSY

Zoono Group Limited (Company) (ASX: ZNO) is pleased to update the market on an exclusive contract signed with Sharpak Aylesham Limited (Sharpak) and the Company’s partner in the food supply chain sector, OSY Group Limited (OSY).

Keep reading...Show less

Latest Press Releases

Related News

×